These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25708506)

  • 1. Initial improvements when converting eyes with treatment-resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2015 Sep; 93(6):e510-1. PubMed ID: 25708506
    [No Abstract]   [Full Text] [Related]  

  • 2. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
    Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
    Narayan DS; Muecke J
    Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
    Nomura Y; Yanagi Y
    Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAVING SIGHT IN NEOVASCULAR AMD.
    Retina; 2020 Jul; 40 Suppl 2():S1-S12. PubMed ID: 32558673
    [No Abstract]   [Full Text] [Related]  

  • 10. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.
    Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK
    Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I; Gianniou C; Dirani A
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration.
    He L; Silva RA; Ayoub N; Moshfeghi DM; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2015 May; 46(5):542-9. PubMed ID: 26057757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.
    Major JC; Wykoff CC; Croft DE; Wang R; Mariani AF; Lehmann AE; Brown DM
    Can J Ophthalmol; 2015 Oct; 50(5):373-7. PubMed ID: 26455973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neovascular Age-Related Macular Degeneration.
    Shao J; Choudhary MM; Schachat AP
    Dev Ophthalmol; 2016; 55():125-36. PubMed ID: 26501146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept.
    Hariri A; Diniz B; Fou LV; Lam LA; Nittala MG; Sadda SR
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):195-200. PubMed ID: 25707044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.
    Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I
    Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials.
    Moshfeghi DM; Hariprasad SM; Marx JL; Thompson D; Soo Y; Gibson A; Saroj N; Vitti R; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):238-44. PubMed ID: 26985797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
    Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
    Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.